Transition From Alendronate to Romosozumab (AMG 785)

Completed · Phase 1

Conditions studied: Osteoporosis

In brief

The purpose of this study is to estimate the percent change from baseline in lumbar spine bone mineral density (BMD) following multiple-dose administrations of romosozumab in postmenopausal women with low BMD previously treated with alendronate.

Key facts

Study ID
NCT01588509
Run by
Amgen
People needed
60
Starts
2012-03-30
Expected to finish
2012-11-21
Last updated by the study team
2019-03-26

Who can join

Age: 55 and older, up to 85. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.